Nick Norwitz MD PhD breaks down new work where scientists built what he calls a living drug, and explains why he links it to GLP-1 in a five-part thread.
Recap by typeshit. Post by Nick Norwitz MD PhD on X.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Lilly Medical points to newly published results from a double-blind, placebo-controlled phase 3 study of its triple-hormone shot in people with diabetes.
Vecchio calls the drugs a fresh start for her life, but Reuters notes the cost came in side effects, including gastrointestinal trouble.
A dietitian researcher covers common gut side effects and why big drops in food intake can leave GLP-1 users short on nutrients, with tips like keeping a food diary.
Loading…